Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine 1998 December;42(4) > The Quarterly Journal of Nuclear Medicine 1998 December;42(4):225-41

ULTIMO FASCICOLO
 

JOURNAL TOOLS

Opzioni di pubblicazione
eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Estratti
Permessi
Share

 

  MOLECULAR MANIPULATION AND PHARMACOKINETICS 

The Quarterly Journal of Nuclear Medicine 1998 December;42(4):225-41

Copyright © 2000 EDIZIONI MINERVA MEDICA

lingua: Inglese

Pharmacokinetics and biodistribution of genetically-engineered antibodies

Colcher D.*, Pavlinkova G., Beresford G., Booth B. J. M., Choudhury A., Batra S. K.

From the Department of Pathology and Microbiology [DC, GP, GB, BJMB] and Department of Biochemistry and Molecular Biology [AC, SKB] University of Nebraska Medical Center, Omaha, Nebrasca, USA


PDF


Monoclonal anti­bod­ies (MAbs), ­because of ­their inher­ent spec­i­fic­ity, are ­ideal tar­get­ing ­agents. They can be ­used to deliv­er radio­nu­clides, tox­ins or cyto­tox­ic ­drugs to a spe­cif­ic tis­sue or malig­nant ­cell pop­u­la­tions. Intact immu­no­glob­u­lin (IgG) mole­cules ­have sev­er­al prac­ti­cal lim­i­ta­tions of ­their phar­ma­col­o­gy; ­their rel­a­tive­ly ­large ­size of approx­i­mate­ly 150,000 dal­tons ­leads to a ­slow clear­ance ­from the ­blood ­pool and the ­body result­ing in sig­nif­i­cant expo­sure to nor­mal ­organs ­with lim­it­ed quan­tities deliv­ered to ­tumors. The IgG mole­cule ­shows a rel­a­tive­ly ­poor dif­fu­sion ­from the vas­cu­la­ture ­into and ­through the ­tumor. Attempts to mod­i­fy the phar­ma­col­o­gy of the Ig mole­cule ­have clas­si­cal­ly ­involved the use of pro­teas­es to gen­er­ate F(ab’)2 and Fab’ frag­ments ­with molec­u­lar ­weights of ≈100,000 and 50,000 dal­tons, respec­tive­ly. Fv frag­ments of IgG are one of the small­est ­size func­tion­al mod­ules of anti­bod­ies ­that ­retain ­high affin­ity bind­ing of an anti­gen. Their small­er ­size, ≈25,000 dal­tons, ­enables bet­ter ­tumor pen­e­tra­tion and ­makes ­them poten­tial­ly ­more use­ful ­than a ­whole anti­body mole­cule for clin­i­cal appli­ca­tions. Molecular clon­ing and expres­sion of the var­i­able ­region ­genes of IgG has great­ly facil­i­tat­ed the gen­er­a­tion of engi­neered anti­bod­ies. A sin­gle-­chain Fv (scFv) recom­bi­nant pro­tein, pre­pared by con­nect­ing ­genes encod­ing for ­heavy-­chain and ­light-­chain var­i­able ­regions at the DNA lev­el by an appro­pri­ate oli­go­nu­cleo­tide link­er, ­clears ­from the ­blood at ­much fast­er ­rate ­than ­intact IgG. The scFv frag­ment can ­retain an anti­gen-bind­ing affin­ity sim­i­lar to ­that of a monov­al­ent Fab’ frag­ment; ­this how­ev­er, rep­re­sents a rel­a­tive ­decrease in bind­ing affin­ity ­when com­pared to ­intact anti­bod­ies. The scFv ­with its fast­er clear­ance and low­er affin­ity ­results in a low­er per­cent-inject­ed ­dose local­iz­ing in ­tumors ­when com­pared to the diva­lent IgG mole­cule. This may be ade­quate for imag­ing but prob­ably not for ther­a­py. The valen­cy of the MAb frag­ment is crit­i­cal for the func­tion­al affin­ity of an anti­body to a ­cell sur­face or a poly­mer­ic anti­gen. In ­attempts to gen­er­ate mul­ti­va­lent ­forms of scFv mole­cules, non-cova­lent­ly ­linked scFv dimer­ic and tri­mer­ic mole­cules, dis­ul­fide ­linked dimer­ic scFvs, as ­well as cova­lent­ly ­linked chi­mer­ic scFvs ­have ­been stud­ied. These mul­ti­va­lent scFvs gen­er­al­ly ­have a high­er func­tion­al affin­ity ­than the monov­al­ent ­form result­ing in bet­ter in ­vivo tar­get­ing. Another way to ­alter the phar­ma­col­o­gy of the scFvs is to mod­i­fy its net ­charge. Charge-mod­i­fied scFvs ­with ­desired iso­electric ­points (pI), ­have ­been pre­pared by insert­ing neg­a­tive­ly ­charged ami­no ­acids on the tem­plate of the var­i­able ­region ­genes. This can ­help to over­come unde­sir­able ele­va­tions in ­renal ­uptake ­seen ­with ­most anti­body frag­ments. In con­clu­sion, genet­ic manip­u­la­tions of the immu­no­glob­u­lin mole­cules are effec­tive ­means of alter­ing stabil­ity, func­tion­al affin­ity, phar­ma­cok­i­net­ics, and bio­dis­trib­u­tion of the anti­bod­ies ­required for the gen­er­a­tion of the “mag­ic ­bullet”.

inizio pagina